

# Viva Leisure Ltd (VVA)

Rating: Buy | Risk: High | Price Target: \$3.60

# 1H20 Leaves VVA On Track to Deliver a Strong FY20 and FY21

V Info				
Key Information Current Price (\$ps)				2.41
12m Target Price (\$	ns)			3.60
Target Price Upside (%)				49.4%
TSR (%)	, , , , , , , , , , , , , , , , , , ,		49.4%	
Reporting Currency	• •		AUD	
Market Cap (\$m)			144.0	
Sector Health Care				
Avg Daily Volume (r	n)			0.2
ASX 200 Weight (%)	•			0%
Fundamentals				
YE 31 Dec (AUD)	FY19A	FY20E	FY21E	FY22E
Sales (\$m)	31.1	58.7	98.2	116.5
NPAT (\$m)	2.9	6.2	11.5	15.1
EPS (cps)	5.4	10.8	19.3	25.3
EPS Growth (%)	(2.1%)	99.8%	78.0%	31.3%
DPS (cps) (AUD)	0.0	0.0	4.6	10.7
Franking (%)	0%	0%	100%	100%
Ratios				
YE 31 Dec	FY19A	FY20E	FY21E	FY22E
P/E (x)	50.7	22.2	12.5	9.5
EV/EBITDA (x)	19.1	9.8	5.8	4.9
Div Yield (%)	0.0%	0.0%	1.9%	4.5%
Payout Ratio (%)	0.0%	0.0%	23.8%	42.4%
<b>Price Performan</b>	ce			
YE 31 Dec	1 Mth	2 Mth	3 Mth	1 Yr
Relative (%)	(12.2%)	(17.1%)	(13.6%)	n/a
Absolute (%)	(15.4%)	(16.0%)	(12.4%)	n/a
Benchmark (%)	(3.2%)	1.1%	1.2%	12.0%



#### **Major Shareholders**

Shja Management	36.1%
Mera Vale No1	15.3%
Bennelong	7.6%
Doma Equities	5.7%
OC Funds	4.8%

#### **Event**

VVA has reported its 1H20 results in line with expectations, FY20 guidance has not changed and expectations regarding further acquisitions and organic growth remain unchanged. Shaw and Partners forecasts, TP and rating also remain unchanged.

#### **Highlights**

- Strong results in line with expectations Revenue +52.7% on pcp to \$23.0m, EBITDA +79.8% on pcp to \$5.6m, NPAT 121% on pcp to \$2.8m (excluding AASB16). The results were supported by a 77% increase in members and 140% increase in locations to 60 facilities. Note statutory results including the new accounting treatment for leases under AASB16 increase EBITDA to \$10.3m and reduce NPAT to \$1.2m.
- The key takeaway Multiple growth drivers are set to continue delivering Drivers include:
  - i) As at the end of December VVA's monthly run rate had it generating \$85m of revenue over a 12 month period,
  - ii) utilisation at 71% reflects acquisitions and new openings that operate below VVA historic and targeted utilisation levels, but more importantly represents upside potential as these facilities are brought up to  $\sim$ 85% utilisation,
  - iii) EBITDA margin improvement from 20.7% to 24.4% reflects the operating leverage in the business which is expected to continue to be a feature of future results as VVA continues to expand the number of facilities and as recent acquisitions which operate at margins well below VVA's are improved,
  - iv) further diversification in VVA's membership base was evident with the ACT now representing 50% of members (from 80%) reflecting the fact that the model that was so successful in the ACT is delivering similar results in new regions such as Albury/Wodonga, and
  - v) location numbers continue to expand, up 140% to 60 over the half ending December 31 and now at 75. VVA expects to have 82 locations by 30 June but has additional leases and acquisitions in its development pipeline that bring the total number of potential facilities to 115.
- Controlling its own destiny VVA is now in position to control its own growth over the
  next few years. With \$27m of cash at the end of December (we estimate cash is now at
  \$12m following acquisitions) and the potential to draw further debt VVA is currently in
  position to acquire sites equating to an estimated \$4m of EBITDA.

### Recommendation

VVA's 1H20 results support earlier expectations that its current run rate will under pin a strong FY20 and FY21. VVA's monthly sales run rate exiting December 2019 was \$7m up from \$2.6m at the end of Dec 2018 which provides significant momentum and upside for the second half and for a full 12 month contribution in 2021. VVA has continued to achieve monthly organic growth since December and has guided to a sales run rate growth on pcp of 112% for the June 2020 month. This will have it on an EBITDA run rate of \$21m at June 30 2020, growing members at 15% pa and with funding to acquire additional facilities setting the company up for a strong performance in FY21. The strong growth outlined above not only looks to be sustainable, but based on FY21 expectations is not fully factored into VVA's share price when compared with ASX listed practice managers. BUY.

Darren Vincent | Senior Analyst

+61 2 9238 1269

dvincent@shawandpartners.com.au




Viva Leisure Ltd Health Care Health Care Equipment & Services FactSet: VVA-AU / Bloomberg: VVA AU

Key Items	Data
Recommendation	BUY
Risk	HIGH
Price (\$ps)	2.41
Target Price (\$ps)	3.60
52 Week Range (\$ps)	-
Shares on Issue (m)	59.8
Market Cap (\$m)	144.0
Enterprise Value (\$m)	139.5
TSR (%)	49.4%
Valuation NPV	Data
Beta	1.50
Cost of Debt (net) (%)	7.9%
Risk Free Rate (%)	4.3%
Terminal Growth (%)	3.0%
WACC (%)	13.8%
Company Description	

Viva Leisure Ltd. operates health clubs in health and leisure industries. It offers customers with membership options and a range of facilities from big box to boutique fitness. The firm's brands include Club Lime, Ladies Only, Psycle Life, Aquatics, Hiit Republic, Swim School, Gymmy PT and Studio by Club Lime. The company was founded by Harry Konstantinou and Angelo Konstantinou on January 12, 2004 and is headquartered in Mitchell, Australia Capital Territory.





Net Debt / EBITDA (x)

Financial Year End: 31 December					
Investment Summary (AUD)	FY18A	FY19A	FY20E	FY21E	FY22E
EPS (Reported) (cps)	5.5	5.4	9.3	16.0	21.5
EPS (Underlying) (cps)	5.5	5.4	10.8	19.3	25.3
EPS (Underlying) Growth (%)	119.7%	(2.1%)	99.8%	78.0%	31.3%
PE (Underlying) (x)	n/a	50.7	22.2	12.5	9.5
EV / EBIT (x)	n/a	27.5	16.8	10.5	8.1
EV / EBITDA (x)	n/a	19.1	9.8	5.8	4.9
DPS (cps) (AUD)	0.0	0.0	0.0	4.6	10.7
Dividend Yield (%)	n/a	0.0%	0.0%	1.9%	4.5%
Franking (%)	0%	0%	0%	100%	100%
Payout Ratio (%)	0.0%	0.0%	0.0%	23.8%	42.4%
Free Cash Flow Yield (%)	n/a	2.1%	(5.6%)	2.3%	4.8%
Profit and Loss (AUD) (m)	FY18A	FY19A	FY20E	FY21E	FY22E
Sales	24.1	31.1	58.7	98.2	116.5
Sales Growth (%)	16.3%	28.9%	88.9%	67.3%	18.6%
EBITDA	5.2	7.2	14.2	25.8	31.7
EBITDA Margin (%) Depreciation & Amortisation	<i>21.6%</i> (1.5)	<i>23.3%</i> (2.2)	<i>24.3%</i> (5.9)	<i>26.3%</i> (11.6)	27.2%
EBIT	(1.5) <b>3.7</b>	(2.2) <b>5.0</b>	(5.9) <b>8.3</b>	(11.6) <b>14.2</b>	(12.5) <b>19.1</b>
EBIT Margin (%)	15.2%	16.2%	14.2%	14.5%	16.4%
Net Interest	(0.5)	(1.1)	(0.8)	(0.6)	(0.8)
Pretax Profit	3.1	4.0	7.5	13.6	18.4
Tax	(0.2)	(1.1)	(2.3)	(4.1)	(5.5)
Tax Rate (%)	(7.1%)	(28.2%)	(30.0%)	(30.0%)	(30.0%)
NPAT Underlying	2.9	2.9	6.2	11.5	15.1
NPAT Reported	2.9	2.9	5.3	9.5	12.8
Cashflow (AUD) (m)	FY18A	FY19A	FY20E	FY21E	FY22E
EBIT	3.7	5.0	8.3	14.2	19.1
Tax Paid	0.0	(0.5)	(2.3)	(4.1)	(5.5)
Net Interest	(0.5)	(0.6)	(1.2)	(1.0)	(1.0)
Depreciation & Amortisation	1.5	2.2	5.9	11.6	12.5
Other	(3.0)	1.2	2.6	1.5	0.7
Operating Cashflow	1.7	7.3	13.4	22.2	25.9
Capex	0.0	0.0	(21.0)	(19.0)	(19.0)
Acquisitions and Investments	0.0	(7.1)	(17.0)	0.0	0.0
Disposal of Fixed Assets/Investments	0.1	0.2	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0
Investing Cashflow	0.1	(7.0)	(38.0)	(19.0)	(19.0)
Free Cashflow	(0.2)	3.1	(7.6)	3.2	6.9
Equity Raised / Bought Back	0.0	22.5	19.0	0.0	0.0
Dividends Paid	0.0	0.0	0.0	0.0	(5.8)
Other	0.6	(5.5)	3.2	(4.0)	(7.0)
Financing Cashflow	0.6	17.1	22.2	(4.0)	(12.8)
Net Change in Cash	2.3	17.5	(2.4)	(0.8)	(5.9)
Balance Sheet (AUD) (m)	FY18A	FY19A	FY20E	FY21E	FY22E
Cash	1.1	14.4	12.0	11.2	5.3
Accounts Receivable	0.1	0.2	0.4	0.6	0.7
Inventory	0.1	0.4	0.4	0.4	0.4
Other Current Assets	0.1	0.0	0.0	0.0	0.0
PPE	9.6	19.2	47.1	46.9	45.5
Goodwill & Intangibles	0.0	6.6	5.7	3.7	1.4
Other Non Current Assets	0.3	n/a	n/a	n/a	n/a
Total Assets	11.4	44.2	69.0	66.2	56.6
Accounts Payable	2.0	2.5	2.9	4.2 2.3	4.8
Short Term Debt Long Term Debt	3.3 4.1	2.3 5.7	2.3		2.3
Income Taxes Payable	4.1 0.5	5.7 1.5	12.5 1.5	14.5 1.5	14.5 1.5
Other	1.6	6.6	5.3	5.3	5.3
Total Liabilities	1.6 11.5	18.5	24.4	27.7	28.3
Total Shareholder Equity	(0.1)	25.8	50.0	59.6	66.6
• •					
Ratios ROE (%)	FY18A (8,489.8%)	FY19A 22.2%	<b>FY20E</b> 16.2%	<b>FY21E</b> 21.1%	<b>FY22E</b> 24.0%
ROE (%) Gearing (%)	(8,489.8%)	(33.3%)	5.3%	21.1% 8.5%	24.0% 14.7%
Not Dobt / ERITDA (v)	101.176	(55.5%)	0.3%	0.3%	14.770

1.2

(0.9)

0.2

0.2

0.4



# Industry conditions are expected to sustain growth

VVA's 1H20 result accelerated its 3 year sales growth trajectory (CAGR of 20%) and reaffirmed its margin improvement of the last few years, each of which look set to improve further over future years as reflected in Figure 1 and 2.

Figure 1: Sales (A\$m) and Gross Margin (%)





Figure 2: Operating cashflow, NPAT & EBITDA (A\$M)



Source: Shaw and Partners

Source: Shaw and Partners

Recent acquisitions and green field developments are expected to see VVA's 'hub and spoke' strategy deliver an increasingly profitable mix of clubs in the future as detailed in Figures 3 and 4.

Figure 3: VVA clubs by type - 2019





Figure 4: Future – Boutique & express no.s are expected to grow




Source: Shaw and Partners

Source: Shaw and Partners

There are ~5,000 businesses within the Australian fitness industry (in all segments). Most of these are franchises of the large industry participants however, there are ~1000 privately owned single club owners and a similar number of clubs owned by multiclub owners as detailed in Figure 5 most of which are in regional Australia where VVA is rolling out new facilities.

Figure 5: Australian Health Club market



Source: Shaw and Partners



# **Key risks**

- VVA's ability to attract and retain members is crucial to its profitability in VVA's home market the ACT it has achieved 10% penetration compared to an industry average national penetration of 15%. This industry leading penetration suggests VVA can build membership in other regions that it is now expanding into.
- VVA may face increased competition from competitors for members and suitable acquisition opportunities.
- VVA operates its facilities from leased premises. There is a risk that leases may not be renewed on acceptable terms, however VVA typically has multiple 5 year options in place.
- Operational risks confronting roll ups are greater than those confronted by established businesses.
- ~40% of VVA's total FY19 revenue was reliant on a single contract (CISAC). We expect it will drop to ~27.3% of total revenue for FY20.
- VVA relies on software and hardware to support the operation of its facilities. Any significant interruption could adversely impact its financial performance.

## **Core drivers and catalyst**

- Improved utilization as recent acquisitions are brought into line with VVA's historic averages,
- Evidence of strong membership growth from the replication of VVA's 'hub and spoke' model in Albury/Wodonga, and
- Delivery of a June 2020 monthly run rate up 112% on pcp as previously guided.



# **Rating Classification**

Buy	Expected to outperform the overall market
Hold	Expected to perform in line with the overall market
Sell	Expected to underperform the overall market
Not Rated	Shaw has issued a factual note on the company but does not have a recommendation

# **Risk Rating**

High	Higher risk than the overall market – investors should be aware this stock may be speculative
Medium	Risk broadly in line with the overall market
Low	Lower risk than the overall market

**RISK STATEMENT:** Where a company is designated as 'High' risk, this means that the analyst has determined that the risk profile for this company is significantly higher than for the market as a whole, and so may not suit all investors. Clients should make an assessment as to whether this stock and its potential price volatility is compatible with their financial objectives. Clients should discuss this stock with their Shaw adviser before making any investment decision.



## **Disclaimer**

Shaw and Partners Limited ABN 24 003 221 583 ("Shaw") is a Participant of ASX Limited, Chi-X Australia Pty Limited and the holder of Australian Financial Services Licence number 236048.

ANALYST CERTIFICATION: The Research Analyst who prepared this report hereby certifies that the views expressed in this document accurately reflect the analyst's personal views about the Company and its financial products. Neither Shaw nor its Research Analysts received any direct financial or non-financial benefits from the company for the production of this document. However, Shaw Research Analysts may receive assistance from the company in preparing their research which can include attending site visits and/or meetings hosted by the company. In some instances, the costs of such site visits or meetings may be met in part or in whole by the company if Shaw considers it is reasonable given the specific circumstances relating to the site visit or meeting. As at the date of this report, the Research Analyst does not hold, either directly or through a controlled entity, securities in the Company that is the subject of this report. Shaw restricts Research Analysts from trading in securities outside of the ASX/S&P100 for which they write research. Other Shaw employees may hold interests in the company.

DISCLAIMER: This report is published by Shaw to its clients by way of general, as opposed to personal, advice. This means it has been prepared for multiple distribution without consideration of your investment objectives, financial situation and needs ("Personal Circumstances"). Accordingly, the advice given is not a recommendation that a particular course of action is suitable for you and the advice is therefore not to be acted on as investment advice. You must assess whether or not the advice is appropriate for your Personal Circumstances before making any investment decisions. You can either make this assessment yourself, or if you require a personal recommendation, you can seek the assistance of your Shaw client adviser. This report is provided to you on the condition that it not be copied, either in whole or in part, distributed to or disclosed to any other person. If you are not the intended recipient, you should destroy the report and advise Shaw that you have done so. This report is published by Shaw in good faith based on the facts known to it at the time of its preparation and does not purport to contain all relevant information with respect to the financial products to which it relates. The research report is current as at the date of publication until it is replaced, updated or withdrawn. Although the report is based on information obtained from sources believed to be reliable, Shaw does not make any representation or warranty that it is accurate, complete or up to date and Shaw accepts no obligation to correct or update the information or opinions in it. If you rely on this report, you do so at your own risk. Any projections are indicative estimates only and may not be realised in the future. Such projections are contingent on matters outside the control of Shaw (including but not limited to market volatility, economic conditions and company-specific fundamentals) and therefore may not be realised in the future. Past performance is not a reliable indicator of future performance. Except to the extent that liability under any law cannot be excluded, Shaw disclaims liability for all loss or damage arising as a result of any opinion, advice, recommendation, representation or information expressly or impliedly published in or in relation to this report notwithstanding any error or omission including negligence.

DISCLOSURE: Shaw will charge commission in relation to client transactions in financial products and Shaw client advisers will receive a share of that commission. Shaw, its authorised representatives, its associates and their respective officers and employees may have earned previously or may in the future earn fees and commission from dealing in the Company's financial products. Shaw acted as Co Manager in the December 2019 placement of VVA securities for which it received fees or will receive fees for acting in this capacity. Accordingly, Shaw may have a conflict of interest which investors should consider before making an investment decision.

RESEARCH TEAM: For analyst qualifications and experience, refer to our website at http://www.shawandpartners.com.au/about/ourpeople/research

RESEARCH POLICY: For an overview of our Research policy, refer to our website at https://www.shawandpartners.com.au/media/1267/ researchpolicy.pdf

If you no longer wish to receive Shaw research, please contact your Financial Adviser to unsubscribe.

Sydney | Head Office Level 7, Chifley Tower 2 Chifley Square Svdnev NSW 2000 Telephone: +61 2 9238 1238 Toll Free: 1800 636 625

Melbourne Level 20 90 Collins Street Melbourne VIC 3000 1800 150 009 Toll Free:

Brisbane Level 28 111 Eagle Street Brisbane QLD 4000 Telephone: +61 3 9268 1000 Telephone: +61 7 3036 2500 Toll Free: 1800 463 972

Adelaide Level 23 91 King William Street Adelaide SA 5000 Toll Free: 1800 636 625

Canberra Level 7 54 Marcus Clarke Street Canberra ACT 2600 Telephone: +61 8 7109 6000 Telephone: +61 2 6113 5300 Toll Free: 1800 636 625

Perth Level 20 108 St Georges Terrace Perth WA 6000

Telephone: +61 8 9263 5200 1800 198 003 Toll Free:

Holder of Australian Financial Services Licence Number 236048 | ABN 24 003 221 583 | Participant of ASX Limited, Chi-X Australia Pty Limited | www.shawandpartners.com.au